Mutual Interaction Between Presynaptic Alpha 2-adrenoceptors and 5-HT1B Receptors on the Sympathetic Nerve Terminals of the Rat Inferior Vena Cava

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 1990 May 1

PMID 1973266

Citations 14

Authors

G J Molderings

M Gothert

Affiliations

Soon will be listed here.

Abstract

Segments of the rat vena cava preincubated with [3H]noradrenaline and superfused with [3H]noradrenaline-free solution containing desipramine and corticosterone were stimulated electrically (standard parameters: 150 mA, 0.3 ms, 0.66 Hz; duration 6 min). In some experiments the stimulation parameters were modified in order to obtain similar absolute release values despite the presence of an alpha-adrenoceptor agonist or antagonist or of 5-hydroxytryptamine (5-HT). In a first set of experiments, the vascular segments were first exposed to an alpha-adrenoceptor ligand, which was kept present throughout the remainder of superfusion, and then to 5-HT. The release-inhibiting effect of 5-HT was attenuated by the alpha 2-adrenoceptor agonists clonidine and B-HT 920 whereas it was enhanced by the alpha-adrenoceptor antagonists phentolamine and idazoxan. The alpha 1-adrenoceptor antagonist prazosin did not change the 5-HT-induced inhibition of noradrenaline (NA) release. In a second set of experiments, 5-HT was administered first and kept present in the superfusion fluid for the remainder of the experiment. In the presence of 5-HT, the overflow-inhibiting effects of B-HT 920 and clonidine and the overflow-enhancing effect of idazoxan were reduced. The results demonstrate that activation of one kind of receptor decreased the inhibition of noradrenaline release produced by activation of the other. These effects were not the consequence of the change of release per se induced by the interacting drugs, since they also occurred when the release was adjusted to similar levels by modification of the stimulation parameters.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Presynaptic Adrenoceptors.

Szabo B Handb Exp Pharmacol. 2024; 285:185-245.

PMID: 38755350 DOI: 10.1007/164_2024_714.

Serotonin and beyond-a tribute to Manfred Göthert (1939-2019).

Bonisch H, Fink K, Malinowska B, Molderings G, Schlicker E Naunyn Schmiedebergs Arch Pharmacol. 2021; 394(9):1829-1867.

PMID: 33991216 PMC: 8376721. DOI: 10.1007/s00210-021-02083-5.

Inhibition of noradrenaline release via presynaptic 5-HT1D alpha receptors in human atrium.

Molderings G, Frolich D, Likungu J, Gothert M Naunyn Schmiedebergs Arch Pharmacol. 1996; 353(3):272-80.

PMID: 8692281 DOI: 10.1007/BF00168628.

Effects of 5-HT receptor agonists on depolarization-induced [3H]-noradrenaline release in rabbit hippocampus and human neocortex.

Allgaier C, Warnke P, Stangl A, Feuerstein T Br J Pharmacol. 1995; 116(2):1769-74.

PMID: 8528558 PMC: 1909076. DOI: 10.1111/j.1476-5381.1995.tb16661.x.

Lack of interaction between alpha 2-adrenoceptors and dopamine D2-receptors in mediating their inhibitory effects on [3H]dopamine release from rat nucleus accumbens slices.

Russell V, Lamm M, Taljaard J Neurochem Res. 1993; 18(3):285-9.

PMID: 8097573 DOI: 10.1007/BF00969084.

References

Gothert M, Kollecker P . Subendothelial beta 2-adrenoceptors in the rat vena cava: facilitation of noradrenaline release via local stimulation of angiotensin II synthesis. Naunyn Schmiedebergs Arch Pharmacol. 1986; 334(2):156-65. DOI: 10.1007/BF00505816. View

Gothert M, Schlicker E, Kollecker P . Receptor-mediated effects of serotonin and 5-methoxytryptamine on noradrenaline release in the rat vena cava and in the heart of the pithed rat. Naunyn Schmiedebergs Arch Pharmacol. 1986; 332(2):124-30. DOI: 10.1007/BF00511401. View

Schoeffter P, Hoyer D . 5-Hydroxytryptamine 5-HT1B and 5-HT1D receptors mediating inhibition of adenylate cyclase activity. Pharmacological comparison with special reference to the effects of yohimbine, rauwolscine and some beta-adrenoceptor antagonists. Naunyn Schmiedebergs Arch Pharmacol. 1989; 340(3):285-92. DOI: 10.1007/BF00168512. View

Limberger N, Fischer M, Wichmann T, Starke K . Phentolamine blocks presynaptic serotonin autoreceptors in rabbit and rat brain cortex. Naunyn Schmiedebergs Arch Pharmacol. 1989; 340(1):52-61. DOI: 10.1007/BF00169207. View

Stratford C, Tan G, Hamblin M, Ciaranello R . Differential inactivation and G protein reconstitution of subtypes of [3H]5-hydroxytryptamine binding sites in brain. Mol Pharmacol. 1988; 34(4):527-36. View

Allgaier C, Jager T, Hertting G . Endogenous noradrenaline impairs the prostaglandin-induced inhibition of noradrenaline release. Naunyn Schmiedebergs Arch Pharmacol. 1989; 340(4):472-4. DOI: 10.1007/BF00167051. View

Jackisch R, Geppert M, Illes P . Characterization of opioid receptors modulating noradrenaline release in the hippocampus of the rabbit. J Neurochem. 1986; 46(6):1802-10. DOI: 10.1111/j.1471-4159.1986.tb08499.x. View

Hoyer D, Middlemiss D . Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain. Trends Pharmacol Sci. 1989; 10(4):130-2. DOI: 10.1016/0165-6147(89)90159-4. View

Allgaier C, Hertting G, Kugelgen O . The adenosine receptor-mediated inhibition of noradrenaline release possibly involves an N-protein and is increased by alpha 2-autoreceptor blockade. Br J Pharmacol. 1987; 90(2):403-12. PMC: 1916948. DOI: 10.1111/j.1476-5381.1987.tb08970.x. View

10.

Paiva M, Caramona M, Osswald W . Intra- and extraneuronal metabolism of 5-hydroxytryptamine in the isolated saphenous vein of the dog. Naunyn Schmiedebergs Arch Pharmacol. 1984; 325(1):62-8. DOI: 10.1007/BF00507055. View

11.

Schoffelmeer A, Putters J, Mulder A . Activation of presynaptic alpha 2-adrenoceptors attenuates the inhibitory effect of mu-opioid receptor agonists on noradrenaline release from brain slices. Naunyn Schmiedebergs Arch Pharmacol. 1986; 333(4):377-80. DOI: 10.1007/BF00500012. View

12.

Loiacono R, Rand M, Story D . Interaction between the inhibitory action of acetylcholine and the alpha-adrenoceptor autoinhibitory feedback system on release of [3H]-noradrenaline from rat atria and rabbit ear artery. Br J Pharmacol. 1985; 84(3):697-705. PMC: 1987138. DOI: 10.1111/j.1476-5381.1985.tb16152.x. View

13.

Allgaier C, Feuerstein T, Jackisch R, Hertting G . Islet-activating protein (pertussis toxin) diminishes alpha 2-adrenoceptor mediated effects on noradrenaline release. Naunyn Schmiedebergs Arch Pharmacol. 1985; 331(2-3):235-9. DOI: 10.1007/BF00634243. View

14.

Schlicker E, Gothert M . Antagonistic properties of quipazine at presynaptic serotonin receptors and alpha-adrenoceptors in rat brain cortex slices. Naunyn Schmiedebergs Arch Pharmacol. 1981; 317(3):204-8. DOI: 10.1007/BF00503817. View

15.

Limberger N, Spath L, Holting T, Starke K . Mutual interaction between presynaptic alpha 2-adrenoceptors and opioid kappa-receptors at the noradrenergic axons of rabbit brain cortex. Naunyn Schmiedebergs Arch Pharmacol. 1986; 334(2):166-71. DOI: 10.1007/BF00505817. View

16.

Kawasaki H, Urabe M, Takasaki K . Presynaptic alpha 2-adrenoceptor modulation of 5-hydroxytryptamine and noradrenaline release from vascular adrenergic nerves. Eur J Pharmacol. 1989; 164(1):35-43. DOI: 10.1016/0014-2999(89)90228-8. View

17.

Molderings G, Gothert M, Fink K, Roth E, Schlicker E . Inhibition of noradrenaline release in the pig coronary artery via a novel serotonin receptor. Eur J Pharmacol. 1989; 164(2):213-22. DOI: 10.1016/0014-2999(89)90461-5. View

18.

Enero M, Saidman B . Possible feed-back inhibition of noradrenaline release by purine compounds. Naunyn Schmiedebergs Arch Pharmacol. 1977; 297(1):39-46. DOI: 10.1007/BF00508808. View

19.

Massingham R, Dubocovich M, Langer S . The role of presynaptic receptors in the cardiovascular actions of N,N-di-n-propyldopamine in the cat and dog. Naunyn Schmiedebergs Arch Pharmacol. 1980; 314(1):17-28. DOI: 10.1007/BF00498427. View

20.

Frankhuijzen A, Wardeh G, Hogenboom F, Mulder A . Alpha 2-adrenoceptor mediated inhibition of the release of radiolabelled 5-hydroxytryptamine and noradrenaline from slices of the dorsal region of the rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1988; 337(3):255-60. DOI: 10.1007/BF00168835. View